Mundipharma today announced that lab testing at the Duke NUS Medical School at Singapore, has confirmed the potency of its BETADINE® antiseptic services and products against the publication coronavirus (SARS-CoV-2) that causes COVID-19 disease.

Testing has demonstrated BETADINE's® strong in vitro virucidal exercise, killing 99.99% of the SARS-CoV-2 virus in 30 seconds.

The investigation was published in the prestigious Infectious Disease and Therapy Journal on 08 July 2020.
<blockquote>These results confirm our view that BETADINE® antiseptic products, used appropriately and in conjunction with other preventative treatment options including PPE, can play a role in limiting the spread of infections, including COVID-19. It also provides the medical community as well as consumers with a science-based assurance that they are using a product that is a proven defense against COVID-19.”<em>Raman Singh, CEO Mundipharma</em></blockquote>
The analysis conducted in Duke-NUS is directed by Laboratory testing performed in the Royal Infectious Diseases Research and Education Center (TIDREC) at the University of Malaya, Malaysia, that additionally attested strong in vitro virucidal exercise, with the analyzed product BETADINE® Gargle and also Mouthwash (1.0percent PVP-I) murdering 99.99% of those SARS-CoV-2 virus at 15 seconds. The journal is published by Springer Nature for the British Dental Association.

Previously, BETADINE® anti-septic products containing povidone iodine (PVP-I) have been demonstrated effective in vitro against a wide array of viruses, for example coronaviruses who have generated major outbreaks like Middle East Respiratory Syndrome (MERS) and Severe Acute Respiratory Syndrome (SARS). The BETADINE® anti-septic range includes Povidone-iodine (PVP-I), that will be remarkably effective against a wide assortment of germs, such as viruses, bacteria and fungi and is typically utilised in hospitals.